Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
766.94-
QQQ
728.181.04%
BTC/USD
84844.504.5403%
DIA
520.440.88%
GLD
399.790.34%
TLT
81.740.6%

Enliven Therapeutics Inc (ELVN) Stock Price, Quote, News & History

ELVNNASDAQ
Trade with Public
Trade with Public
$49.45
-0.79-1.57%
At close: Sep 17, 5:00 PM EST
$49.35
-0.89-1.77%
Pre-Market: 7:37 AM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Enliven Therapeutics (ELVN) Stock Price, Quote, News & History | Benzinga

Key Statistics

Open
-
Close
$49.45
Volume / Avg.
308.00 / 1.31M
Day Range
- - -
52 Wk Range
14.79 - 62.32
Market Cap
$3.53B
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
28
Short Interest
17.54%
Days to Cover
11.07

Recent Enliven Therapeutics, Inc. News

Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says

William Blair initiates Enliven Therapeutics (ELVN) with Outperform, highlighting ELVN-001's strong CML trial data & $8.8B market potential.
Vandana Singh

Crude Oil Edges Higher; Driven Brands Posts Upbeat Earnings

US stocks rise with Nasdaq up 150 points. Dow up 0.54%, Nasdaq up 0.63%, S&P 500 up 0.26%. Industrials and Enliven Therapeutics lead gains. Dana Inc and Oracle Corp down. Oil up 0.7%, gold down 0.7%. European and Asian markets mixed. Initial jobless claims and producer prices higher than expected.
Avi Kapoor

Stitch Fix, Intel, KLA And Other Big Stocks Moving Higher On Thursday

Stitch Fix (SFIX) reported better-than-expected financial results, causing its shares to jump 15.8%. Other big gainers include Velo3D, Virgin Galactic, and Intel.
Avi Kapoor

This Grand Canyon Education Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday

Wall Street analysts changed outlook on top names. Check analyst ratings page for upgrades, downgrades, and initiations. See analysts' views on LOPE stock.
Avi Kapoor

CG Oncology, Rich Sparkle Holdings, Liquidia And Other Big Stocks Moving Higher On Friday

Avi Kapoor

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change

Cash Flows

Operating Cash Flow (TTM)
-66.94M
Investing Cash Flow (TTM)
-390.72M
Financing Cash Flow (TTM)
473.73M
Free Cash Flow (TTM)
-67.04M
Capital Expenditure (TTM)
-98.00K
Net Change in Cash (TTM)
16.07M

Analyst Trends and Forecast

2
Mar
1
May
3
Jun
3
Jul
6
Aug
Buy
Hold
Sell
Strong Sell

Analyst Rating and Forecast

12345
4.2
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Valuation Metrics

Enterprise Value
$2.73B
PE Ratio (TTM)
-
PE Ratio (FWD)
-
PEG Ratio (TTM)
-
PS Ratio (TTM)
-
PB Ratio (TTM)
4.04
Earnings Yield % (TTM)
-3.34%
Earnings Yield % (FWD)
-0.43%
EV / EBITDA (TTM)
-
Price / EBITDA (TTM)
-
Price / Free Cash Flow (TTM)
-
Book Value / Share
$12.22

Company Debt

Total Debt
-
LT Debt
-
LT Debt Issuance (TTM)
-
LT Debt Repayment (TTM)
-
Total Cash
$135.51M
Debt to Equity
0.00
Issuance of Debt (TTM)
-
Repayment of Debt (TTM)
-

Key Statistics

Open
-
Close
$49.45
Volume / Avg.
308.00 / 1.31M
Day Range
- - -
52 Wk Range
14.79 - 62.32
Market Cap
$3.53B
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
28
Short Interest
17.54%
Days to Cover
11.07

About

Sector
Health Care
Industry
Pharmaceuticals
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusi...
Show More
Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

FAQ

Q

How do I buy Enliven Therapeutics (ELVN) stock?

A

You can purchase shares of Enliven Therapeutics (NASDAQ:ELVN) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Enliven Therapeutics (ELVN) competitors?

Q

What is the forecast, or price target, for Enliven Therapeutics (ELVN) stock?

A

Enliven Therapeutics has a consensus price target of $64.60.

Q

What is the current price for Enliven Therapeutics (ELVN)?

A

The stock price for Enliven Therapeutics (NASDAQ: ELVN) is $49.35 last updated September 21, 2026 at 4:03 AM EDT.

Q

Does Enliven Therapeutics (ELVN) pay a dividend?

A

There are no upcoming dividends for Enliven Therapeutics.

Q

When is Enliven Therapeutics (NASDAQ:ELVN) reporting earnings?

A

Enliven Therapeutics does not have any upcoming earnings scheduled.

Q

Is Enliven Therapeutics (ELVN) going to split?

A

There is no upcoming split for Enliven Therapeutics.

Q

What sector and industry does Enliven Therapeutics (ELVN) operate in?

A

Enliven Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved